stockrow
Friday 6 November 2026
Export QSI’s income statement to Excel — free account
Quantum-Si Incorporated
QSI Healthcare Medical Devices
Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024.
- Revenue
- −61.6%
- EPS
- +41.2%
- Free cash flow
- +37.5%
Quarter to September 2026, against a year earlier
1.32
0.15
+12.82%
Follow QSI
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
185.23 | 120.77 | 90.00 | 89.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.44) | (10.51) | (6.50) | (13.31) | |
P/B ratio |
1.46 | 1.08 | 0.83 | 0.99 | |
Price to Tangible BV |
1.46 | 1.08 | 0.83 | 0.99 | |
EV/Sales |
103.40 | 51.15 | 21.24 | 22.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.62) | (0.89) | (0.42) | (0.58) | |
EV/FCF |
(1.61) | (0.88) | (0.41) | (0.56) | |
Quick Ratio |
8.88 | 9.36 | 11.91 | 7.30 | |
Current Ratio |
9.64 | 9.97 | 12.60 | 7.64 | |
Net Debt/EBITDA |
4.47 | 4.45 | 5.37 | 7.58 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.92 | 0.78 | 1.18 | 0.93 | |
Capex/Depreciation |
(0.15) | (0.15) | (0.83) | (0.04) | |
Research and Development Expense of Revenue |
6,499.53% | 4,600.00% | 5,615.12% | 2,427.05% | |
Selling, General and Administrative Expense of Revenue |
4,750.47% | 2,900.29% | 3,736.43% | 2,277.16% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,337.74% | 886.63% | 994.19% | 596.01% | |
Graham Net Nets |
0.43 | 0.55 | 0.73 | 0.69 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(36.45%) | (51.69%) | (66.23%) | (47.27%) | |
Free Cash Flow Yield |
(34.72%) | (48.33%) | (57.41%) | (44.70%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.09) | (0.08) | (0.12) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.08) | (0.12) | (0.08) | |
Cash per Share |
0.47 | 0.51 | 0.59 | 0.82 | |
Shareholders Equity per Share |
0.73 | 0.83 | 0.93 | 1.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.73 | 0.83 | 0.93 | 1.11 | |
Free Cash Flow |
(20.58) | (18.52) | (25.92) | (16.33) | |
Working Capital |
100.72 | 107.14 | 124.26 | 152.84 | |
Capital Expenditures |
(0.09) | (0.08) | (0.28) | 0.02 | |
Net Current Asset Value |
99.70 | 105.71 | 122.36 | 150.48 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.45 | 0.23 | 1.08 | (0.04) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 2.81 | 0.62 | 3.27 | |
Average Payables |
1.38 | 1.91 | 1.84 | 1.78 | |
Average Inventory |
2.58 | 2.97 | 3.31 | 3.63 | |
Average Assets |
216.51 | 223.99 | 242.29 | 246.74 | |
Average Common Equity |
197.69 | 200.59 | 223.83 | 217.82 |
Columns are period end dates · fundamentals updated 5 Nov 2026